CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
785.08MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.59xvs all stocks
52-Week Change
210.37%vs all stocks
Market Capitalization
785.08MUSDvs all stocks (USD)
Enterprise Value
567.49MUSDvs all stocks (USD)
Forward P/E
-7.71xvs Biotechnology peers
Price to Book (MRQ)
3.61xvs Biotechnology peers
Enterprise to EBITDA
-7.30xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-20.93%vs Biotechnology peers
Return on Equity (TTM)
-31.26%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
-58.13MUSDvs all stocks (USD)
EBITDA (TTM)
-77.73MUSDvs all stocks (USD)
Net Income (TTM)
-69.71MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-54.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-31.56MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-79.47MUSDvs all stocks (USD)
Pre-tax Income
-69.79MUSDFY2025 · Dec 31, 2025Net Income
-69.79MUSDFY2025 · Dec 31, 2025EBIT
-79.47MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-78.84MUSDFY2025 · Dec 31, 2025Research & Development
59.13MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
20.34MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.68MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-69.79MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-49.73MUSDFY2025 · Dec 31, 2025Free Cash Flow
-49.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
16.86MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-69.79MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
622.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.55MUSDFY2025 · Dec 31, 2025Other Non-cash Items
406.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.49MUSDFY2025 · Dec 31, 2025Capital Expenditures
-193.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-291.78MUSDFY2025 · Dec 31, 2025Sale of Investments
314.88MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
22.91MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
24.85MUSDFY2025 · Dec 31, 2025Shares Outstanding
62.44MSharesUpdated Jul 18, 2026Float Shares
32.87MSharesUpdated Jul 18, 2026Shares Short
5.72MSharesUpdated Jul 18, 2026Short Ratio
6.17daysvs all stocks
Short % of Shares Outstanding
12.13%vs all stocks
% Held by Insiders
31.93%vs all stocks
% Held by Institutions
62.12%vs all stocks
Total Cash (MRQ)
222.82MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.57USDUpdated Jul 18, 2026Total Debt (MRQ)
2.73MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0125xvs Biotechnology peers
Current Ratio (MRQ)
22.28xvs Biotechnology peers
Book Value per Share (MRQ)
3.49USDUpdated Jul 18, 2026Total Assets
226.20MUSDvs all stocks (USD)
Total Current Assets
223.78MUSDFY2025 · Dec 31, 2025Total Liabilities
13.70MUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.42MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
645.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
13.05MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
16.86MUSDFY2025 · Dec 31, 2025Other Short-term Investments
202.99MUSDFY2025 · Dec 31, 2025Accounts Payable
2.31MUSDFY2025 · Dec 31, 2025Short-term Debt
890.00KUSDFY2025 · Dec 31, 2025Long-term Debt
645.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-297.01MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
212.50MUSDvs all stocks (USD)
52-Week Low
3.76USDUpdated Jul 18, 202652-Week High
17.25USDUpdated Jul 18, 202652-Week Change
210.37%vs all stocks
Beta
1.59xvs all stocks
50-Day MA
12.76USDUpdated Jul 18, 2026200-Day MA
10.33USDUpdated Jul 18, 2026Avg 10-Day Volume
871.55KSharesUpdated Jul 18, 2026Avg 30-Day Volume
894.10KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.20USDUpdated Jul 18, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.67
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Si-Bone Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Relay Therapeutics Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration
Johnson Outdoors Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration
Scorpio Tankers Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration